Acupuncture vs no intervention
All‐cause mortality · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Findings
What do systematic reviews say?
502 questions · 519 findings · 57 reviews · Hepato-Biliary
No studies found 131 · 25.2%GRADE not reported 11 · 2.1%Very low 302 · 58.2%Low 46 · 8.9%Moderate 27 · 5.2%High 2 · 0.4%
Acupuncture vs no intervention
Proportion of participants with 1 or more serious adverse events · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Acupuncture vs no intervention
Health‐related quality of life · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Acupuncture vs no intervention
Hepatitis B‐related mortality · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Acupuncture vs no intervention
Hepatitis B‐related morbidity · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Acupuncture vs no intervention
Non‐serious adverse events Maximum · chronic hepatitis B
It is very uncertain whether acupuncture changes proportion of participants with 1 or more adverse events considered… compared with no intervention (very low certainty).
1 finding from 1 review
- RR 0.67 [0.43, 1.06]3 studies · 203 participantsVery low
Acupuncture vs no intervention
Exploratory outcome: Proportion of participants with detectable HBV‐DNA (at maximum · chronic hepatitis B
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
L‐ornithine L‐aspartate vs placebo or no intervention
All‐cause mortality
It is very uncertain whether L‐ornithine L aspartate changes mortality compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2018 · Cochrane Headline outcomes onlyRR 0.42 [0.24, 0.72]19 studies · 1489 participantsVery low
L‐ornithine L‐aspartate vs placebo or no intervention
Hepatic encephalopathy
It is very uncertain whether L‐ornithine L aspartate changes hepatic encephalopathy assessed based on neurocognitive manifestations compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2018 · Cochrane Headline outcomes onlyRR 0.7 [0.59, 0.83]22 studies · 1375 participantsVery low
L‐ornithine L‐aspartate vs placebo or no intervention
Serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2018 · Cochrane Headline outcomes onlyRR 0.63 [0.45, 0.9]19 studies · 1489 participantsVery low
L‐ornithine L‐aspartate vs placebo or no intervention
QoL
1 finding from 1 review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2018 · Cochrane Headline outcomes onlyno estimate extractedStudies not reportedVery low
L‐ornithine L‐aspartate vs placebo or no intervention
Non‐serious adverse events assessed using ICH‐GCP
It is very uncertain whether L‐ornithine L aspartate changes non‐serious adverse events assessed using ICH‐GCP compared with placebo or no intervention (very low certainty).
1 finding from 1 review
- L‐ornithine L‐aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis 2018 · Cochrane Headline outcomes onlyRR 1.15 [0.75, 1.77]14 studies · 1076 participantsVery low
Hepatitis B immunoglobulin (HBIG) vs no intervention
All‐cause mortality or other serous adverse events of the newborn
1 finding from 1 review
- Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus 2017 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 1 participantsGRADE not reported
Hepatitis B immunoglobulin (HBIG) vs no intervention
All‐cause mortality or other serous adverse events of the mothers
1 finding from 1 review
- Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus 2017 · Cochrane Headline outcomes onlyno estimate extracted0 studies · 1 participantsGRADE not reported
Hepatitis B immunoglobulin (HBIG) vs no intervention
Newborn with HBsAg‐positive result
It is very uncertain whether hepatitis B immunoglobulin (HBIG) changes newborn with HBsAg‐positive result compared with no intervention (very low certainty).
1 finding from 1 review
- Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus 2017 · Cochrane Headline outcomes onlyRR 0.3 [0.24, 0.38]29 studies · 5310 participantsVery low
Hepatitis B immunoglobulin (HBIG) vs no intervention
Newborn with HBeAg‐positive result
It is very uncertain whether hepatitis B immunoglobulin (HBIG) changes newborn with HBeAg‐positive result compared with no intervention (very low certainty).
1 finding from 1 review
- Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus 2017 · Cochrane Headline outcomes onlyRR 0.68 [0.43, 1.05]7 studies · 1764 participantsVery low
Hepatitis B immunoglobulin (HBIG) vs no intervention
Newborn with HBV‐DNA‐positive result
Hepatitis B immunoglobulin (HBIG) may leads to lower newborn with HBV‐DNA‐positive result compared with no intervention (low certainty).
1 finding from 1 review
- Hepatitis B immunoglobulin during pregnancy for prevention of mother‐to‐child transmission of hepatitis B virus 2017 · Cochrane Headline outcomes onlyRR 0.25 [0.15, 0.42]16 studies · 2130 participantsLow
Nutrition support vs no intervention, placebo, or treatment
All‐cause mortality · hospitalised adults at nutritional risk
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found
Nutrition support vs no intervention, placebo, or treatment
at maximum · hospitalised adults at nutritional risk
Nutrition support may leads to lower ‐ at maximum compared with no intervention, placebo, or treatment (low certainty).
3 findings from 1 review
- RR 0.93 [0.88, 0.99]127 studies · 23170 participantsLow
- RR 0.91 [0.85, 0.97]137 studies · 23413 participantsLow
- no estimate extracted2 studies · 3961 participantsVery low
Nutrition support vs no intervention, placebo, or treatment
Serious adverse events · hospitalised adults at nutritional risk
The review found no eligible studies for this question.
1 finding from 1 review
- no estimate extractedStudies not reportedNo studies found